A Study to Evaluate Indocyanine Green Lymphangiography to Improve Lymphadenectomy in Gastric Cancer Patients
Indocyanine Green Lymphangiography as a Tool for Improving Lymphadenectomy in Gastric Cancer
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Phase
Phase
- Phase 4
Contacts and Locations
Study Locations
-
-
Florida
-
Jacksonville, Florida, United States, 32224
- Mayo Clinic in Florida
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Patients ≥ 18 and ≤ 75 years of age.
- Primary gastric adenocarcinoma of any histological subtype confirmed pathologically by endoscopic biopsy.
- Clinical stage tumor T1-4a (cT1-4a), N -/+, M0 at preoperative evaluation according to the American Joint Committee on Cancer (AJCC) Cancer Staging Manual Seventh Edition.
- No distant metastasis, no direct invasion of adjacent organs such as pancreas and spleen in preoperative exams.
- American Society of Anesthesiology score (ASA) class I, II, or III.
- Written informed consent.
Exclusion Criteria:
- Patients ≤ 18 and ≥ 75 years of age.
- History of previous upper abdominal surgery (except laparoscopic cholecystectomy).
- History of previous gastrectomy, endoscopic mucosal resection or endoscopic submucosal dissection.
- History of allergy to iodine agents.
- History of other malignant disease within past five years.
- Emergency surgery due to complication caused by gastric cancer, such as bleeding obstruction or perforation.
- Patients intraoperatively/postoperatively confirmed as T4b.
- Patients intraoperatively confirmed as unable to complete D2 lymph node dissection or R0 dissection.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Diagnostic
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Other: Intervention
Injection of Indocyamine Green.
|
A one time injection of IDC prior to the day of scheduled surgery.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Positive ICG fluorescence lymph nodes
Time Frame: Approximately 30-90 days after surgery
|
Total number of lymph nodes removed after surgery that are positive for ICG fluorescence
|
Approximately 30-90 days after surgery
|
|
Disease positive lymph nodes
Time Frame: Approximately 30-90 days after surgery
|
Number of ICG positive lymph nodes that are also positive for disease
|
Approximately 30-90 days after surgery
|
|
Number of lymph nodes removed for each lymphatic station of gastrectomy
Time Frame: Approximately 30-90 days after surgery
|
Total number of lymph nodes removed for each lymphatic station of gastrectomy with NIR+ICG vs gastrectomy without NIR+ICG
|
Approximately 30-90 days after surgery
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Enrique F Elli, MD, Mayo Clinic
Publications and helpful links
Helpful Links
Study record dates
Study Major Dates
Study Start (Estimated)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- 20-002747
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.